• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A leopard can't change its spots: can a T790M mutation-positive cancer change its spots after epidermal growth factor receptor-tyrosine kinase inhibitor therapy?

作者信息

Obayashi Kai, Shimizu Kimihiro, Nakazawa Seshiru, Ohtaki Yoichi, Kawatani Natsuko, Takashi Ibe, Yajima Toshiki, Mogi Akira, Shirabe Ken

机构信息

Division of General Thoracic Surgery, Integrative Center of General Surgery, Gunma University Hospital, Gunma, Japan.

出版信息

J Thorac Dis. 2018 Nov;10(Suppl 33):S4113-S4116. doi: 10.21037/jtd.2018.10.53.

DOI:10.21037/jtd.2018.10.53
PMID:30631569
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6297530/
Abstract
摘要

相似文献

1
A leopard can't change its spots: can a T790M mutation-positive cancer change its spots after epidermal growth factor receptor-tyrosine kinase inhibitor therapy?江山易改，本性难移：表皮生长因子受体-酪氨酸激酶抑制剂治疗后，T790M突变阳性的癌症能改变其特性吗？
J Thorac Dis. 2018 Nov;10(Suppl 33):S4113-S4116. doi: 10.21037/jtd.2018.10.53.
2
Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: Comparison between T790M mutation-positive and mutation-negative populations.表皮生长因子受体酪氨酸激酶抑制剂获得性耐药的非小细胞肺癌患者的再次活检：T790M 突变阳性和突变阴性人群的比较。
Cancer. 2013 Dec 15;119(24):4325-32. doi: 10.1002/cncr.28364. Epub 2013 Sep 16.
3
JAK3 inhibitor VI is a mutant specific inhibitor for epidermal growth factor receptor with the gatekeeper mutation T790M.JAK3抑制剂VI是一种针对具有守门人突变T790M的表皮生长因子受体的突变特异性抑制剂。
World J Biol Chem. 2015 Nov 26;6(4):409-18. doi: 10.4331/wjbc.v6.i4.409.
4
Non-Small Cell Lung Cancer with Resistance to EGFR-TKI Therapy: CT Characteristics of T790M Mutation-positive Cancer.表皮生长因子受体酪氨酸激酶抑制剂耐药的非小细胞肺癌：T790M 突变阳性肿瘤的 CT 特征。
Radiology. 2018 Oct;289(1):227-237. doi: 10.1148/radiol.2018180070. Epub 2018 Jul 17.
5
Importance of repeat tissue biopsy and tissue-based epidermal growth factor receptor T790M testing in progressed nonsmall cell lung carcinoma patients upon negative plasma genotyping for selection of third-generation tyrosine kinase inhibitor therapy: A case study.对于血浆基因分型为阴性的进展期非小细胞肺癌患者，重复组织活检和基于组织的表皮生长因子受体T790M检测在选择第三代酪氨酸激酶抑制剂治疗中的重要性：一项病例研究
Indian J Cancer. 2017 Dec;54(Supplement):S65-S66. doi: 10.4103/ijc.IJC_545_17.
6
No Therapeutic Effect of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Retreatment Despite T790M Disappearance: Case Report of 3 Cases.表皮生长因子受体酪氨酸激酶抑制剂再治疗无治疗效果，尽管 T790M 消失：3 例病例报告。
Chemotherapy. 2018;63(4):198-202. doi: 10.1159/000491937. Epub 2018 Aug 24.
7
Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics.用于表皮生长因子受体基因突变阳性非小细胞肺癌的酪氨酸激酶抑制剂：治疗学最新进展
J Oncol Pharm Pract. 2016 Jun;22(3):461-76. doi: 10.1177/1078155215577810. Epub 2015 Apr 8.
8
Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer.治疗前表皮生长因子受体 (EGFR) T790M 突变可预测非小细胞肺癌患者对 EGFR 酪氨酸激酶抑制剂反应持续时间更短。
J Clin Oncol. 2012 Feb 1;30(4):433-40. doi: 10.1200/JCO.2011.38.3224. Epub 2012 Jan 3.
9
Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.基于皮升液滴数字聚合酶链反应的游离血浆DNA分析，以评估肺腺癌中对酪氨酸激酶抑制剂产生耐药性的表皮生长因子受体突变
Oncologist. 2016 Feb;21(2):156-64. doi: 10.1634/theoncologist.2015-0288. Epub 2016 Jan 14.
10
Epidermal growth factor receptor T790M mutation: A major culprit in the progression of epidermal growth factor receptor-driven non-small cell lung cancer and the role of repeat biopsy.表皮生长因子受体T790M突变：表皮生长因子受体驱动的非小细胞肺癌进展的主要元凶及重复活检的作用
Indian J Cancer. 2017 Dec;54(Supplement):S15-S24. doi: 10.4103/ijc.IJC_510_17.

引用本文的文献

1
Evaluation of the Effect of Wheat Germ Oil and Olmutinib on the Thioacetamide-Induced Liver and Kidney Toxicity in Mice.小麦胚芽油和奥莫替尼对硫代乙酰胺诱导的小鼠肝肾毒性影响的评估
Life (Basel). 2022 Jun 15;12(6):900. doi: 10.3390/life12060900.

本文引用的文献

1
Non-Small Cell Lung Cancer with Resistance to EGFR-TKI Therapy: CT Characteristics of T790M Mutation-positive Cancer.表皮生长因子受体酪氨酸激酶抑制剂耐药的非小细胞肺癌：T790M 突变阳性肿瘤的 CT 特征。
Radiology. 2018 Oct;289(1):227-237. doi: 10.1148/radiol.2018180070. Epub 2018 Jul 17.
2
Computed tomography and clinical features associated with epidermal growth factor receptor mutation status in stage I/II lung adenocarcinoma.计算机断层扫描与表皮生长因子受体突变状态相关的临床特征在 I/II 期肺腺癌。
Thorac Cancer. 2017 May;8(3):260-270. doi: 10.1111/1759-7714.12436. Epub 2017 Apr 6.
3
Air bronchogram: A potential indicator of epidermal growth factor receptor mutation in pulmonary subsolid nodules.空气支气管征：肺亚实性结节中表皮生长因子受体突变的潜在指标。
Lung Cancer. 2016 Aug;98:22-28. doi: 10.1016/j.lungcan.2016.05.009. Epub 2016 May 13.
4
Olmutinib: First Global Approval.奥木替尼：全球首次获批。
Drugs. 2016 Jul;76(11):1153-7. doi: 10.1007/s40265-016-0606-z.
5
CT Features Associated with Epidermal Growth Factor Receptor Mutation Status in Patients with Lung Adenocarcinoma.肺腺癌患者中与表皮生长因子受体突变状态相关的CT特征
Radiology. 2016 Jul;280(1):271-80. doi: 10.1148/radiol.2016151455. Epub 2016 Mar 3.
6
CT Features of Epidermal Growth Factor Receptor-Mutated Adenocarcinoma of the Lung: Comparison with Nonmutated Adenocarcinoma.肺表皮生长因子受体突变型腺癌的 CT 特征：与非突变型腺癌的比较。
J Thorac Oncol. 2016 Jun;11(6):819-26. doi: 10.1016/j.jtho.2016.02.010. Epub 2016 Feb 23.
7
Radiogenomic correlation in lung adenocarcinoma with epidermal growth factor receptor mutations: Imaging features and histological subtypes.具有表皮生长因子受体突变的肺腺癌的放射基因组相关性：影像学特征和组织学亚型
Eur Radiol. 2016 Oct;26(10):3660-8. doi: 10.1007/s00330-015-4196-z. Epub 2016 Jan 19.
8
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.纳武利尤单抗对比多西他赛治疗晚期非鳞状非小细胞肺癌
N Engl J Med. 2015 Oct 22;373(17):1627-39. doi: 10.1056/NEJMoa1507643. Epub 2015 Sep 27.
9
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.纳武单抗与多西他赛治疗晚期鳞状细胞非小细胞肺癌的疗效比较
N Engl J Med. 2015 Jul 9;373(2):123-35. doi: 10.1056/NEJMoa1504627. Epub 2015 May 31.
10
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.阿法替尼治疗表皮生长因子受体抑制剂耐药的非小细胞肺癌
N Engl J Med. 2015 Apr 30;372(18):1689-99. doi: 10.1056/NEJMoa1411817.